-$0.15 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter

Wall Street brokerages forecast that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will report ($0.15) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.16). Achillion Pharmaceuticals posted earnings of ($0.03) per share in the same quarter last year, which would suggest a negative year over year growth rate of 400%. The company is scheduled to report its next quarterly earnings results on Thursday, February 22nd.

On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.63) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.60). For the next financial year, analysts forecast that the firm will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.79) to ($0.55). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same period last year, the firm earned ($0.15) earnings per share.

Several equities analysts have weighed in on ACHN shares. BidaskClub cut Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Chardan Capital lowered their price target on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, August 9th. Maxim Group set a $7.00 price target on Achillion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Robert W. Baird cut Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target for the company. in a report on Thursday, August 10th. Finally, Zacks Investment Research cut Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $5.29.

In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 7.24% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its position in shares of Achillion Pharmaceuticals by 51.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 613,006 shares of the biopharmaceutical company’s stock valued at $2,581,000 after buying an additional 207,204 shares during the last quarter. Deschutes Portfolio Strategy LLC grew its position in shares of Achillion Pharmaceuticals by 358.6% in the 2nd quarter. Deschutes Portfolio Strategy LLC now owns 116,630 shares of the biopharmaceutical company’s stock valued at $535,000 after buying an additional 91,200 shares during the last quarter. Senzar Asset Management LLC bought a new stake in shares of Achillion Pharmaceuticals in the 2nd quarter valued at about $4,966,000. Candriam Luxembourg S.C.A. bought a new stake in shares of Achillion Pharmaceuticals in the 3rd quarter valued at about $1,976,000. Finally, Bank of New York Mellon Corp grew its position in shares of Achillion Pharmaceuticals by 11.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 611,634 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 62,515 shares during the last quarter. Institutional investors and hedge funds own 76.98% of the company’s stock.

Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded down $0.10 during midday trading on Friday, reaching $3.02. The company’s stock had a trading volume of 3,914,093 shares, compared to its average volume of 2,396,773. Achillion Pharmaceuticals has a 52-week low of $2.92 and a 52-week high of $5.66.

ILLEGAL ACTIVITY WARNING: “-$0.15 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/03/0-15-eps-expected-for-achillion-pharmaceuticals-inc-achn-this-quarter-2.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply